Related Experiment Video
Updated: Jun 14, 2026
06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
Pre-dementia Alzheimer's trials: overview
1Department of Neurosciences, UCSD, USA.
The Journal of Nutrition, Health & Aging
|March 23, 2010
Summary
Recent Alzheimer's disease drug trials failed, possibly due to late treatment. Early intervention with disease-modifying therapies is crucial for future Alzheimer's treatment success.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Medicine
Background:
- Numerous clinical trials for Alzheimer's disease (AD) modifying agents have yielded negative results, fostering pessimism.
- The limited efficacy observed may stem from initiating treatments when significant neurodegeneration has already occurred.
Purpose of the Study:
- To emphasize the need for developing methodologies to test disease-modifying treatments in the early stages of Alzheimer's pathology.
- To highlight the potential for greater clinical benefits when pathophysiologic mechanisms are modulated early in the disease course.
Main Methods:
- This study is a conceptual analysis and review of existing clinical trial data and pathological progression models in Alzheimer's disease.
- It synthesizes findings to propose a strategic shift in therapeutic development and testing protocols.
Main Results:
- The advanced stage of neurodegeneration at dementia onset is a significant factor limiting the efficacy of current therapeutic strategies.
- Early-stage intervention holds greater promise for successful modulation of disease processes.
Conclusions:
- A paradigm shift towards early-stage intervention is essential for advancing Alzheimer's disease treatment.
- Developing and validating methodologies for early-stage testing of disease-modifying therapies is paramount for future therapeutic success in Alzheimer's disease.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...